Invasive fungal infections (IFIs) are one of the most significant public health challenges worldwide. Yet, research and communication thereof were left behind for a long time, until the WHO published a priority pathogens list to guide research, development, and public health action in October 2022. Indeed, due to the rising number of immunocompromised patients at risk and the high level of morbidity, mortality, and economic burden they entail, especially in low- and middle-income countries, IFIs are a serious public health threat. Fungal infections due to dimorphic fungi face additional challenges such as limited knowledge outside of endemic areas and restricted availability of antifungal molecules in areas affected by these infections. The number of related deaths per year is estimated at 2.5 million, but non-governmental organisations make a wider estimation, due to the difficulties in early in vitro diagnostic and troublesome collection and analysis of epidemiological data. Despite this fact, the therapeutic toolbox addressing these infections remains limited, with only four main families of molecules available so far. The antifungal therapeutic supply is composed of very toxic polyenes, the weakly selective and nearly unused 5-fluorocytosine, and azoles, some of which are becoming increasingly inefficient against IFIs. In the 2000–2020s, the fourth arising family consisted of safer semisynthetic echinocandins. Unfortunately, nowadays, more and more fungal isolates encountered in intensive care units exhibit a low susceptibility to echinocandins or are even multiresistant. In this review, we expose the current treatments available to fight against invasive fungal infections. We recall the discovery and physico-chemical aspects of these substances leading to structure/activity and structure/properties relationships. We particularly focus on the to-date resistances and their molecular mechanisms. We finally list some of the most relevant antifungal drug candidates, as they were freshly overviewed by the World Health Organization in April 2025, highlighting the importance of the molecular dimension of this pursuit toward the expansion of the antifungal therapeutic toolbox.
21 September 2023 in The Journal of Organic Chemistry
Novel C,C-glycosyl amino acids were accessed by means of an iron-catalyzed hydrogen atom transfer sequence. Crucially, two-fold diastereocontrol could be achieved in the ‘matched’ coupling of exo-d-glycals with an enantiopure dehydroalanine acceptor.
Echinocandins (ECs) are semisynthetic lipocyclohexapeptides introduced in the 2000s to treat invasive fungal infections. They selectively and safely inhibit fungal β-(1,3)-D-glucan synthase, a key enzyme for fungal cell wall integrity, but their precise mechanism remains unclear. Their widespread use has led to emerging resistances, underscoring the need for molecular probes to investigate their action and resistance mechanisms. Due to their structural complexity, only few total syntheses and very limited fluorescent analogues have been reported. Here, we present a solid-phase peptide synthesis (SPPS) strategy to readily access to the EC pharmacophore and to novel fluorescent analogues. Using a safety-catch linker resin, cyclization and cleavage are efficiently combined, affording high-purity cyclic lipopeptides with simplifiedpurification step. Depending on the design, fluorescent tags were introduced either on-resin or in solution via bioconjugation. Several analogues retained antifungal activity against Candida albicans, and their interaction with fungal cells was visualized by confocal microscopy. This versatile methodology delivers some of the first fully synthetic fluorescent echinocandins, providing powerful tools to explore their mechanisms of action and fungal resistance.